{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:12:50Z","timestamp":1794867170343,"version":"4.9.1"},"reference-count":76,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Inhaled antibiotics have been used to treat chronic airway infections since the 1940s. The earliest experience with inhaled antibiotics involved aerosolizing antibiotics designed for parenteral administration. These formulations caused significant bronchial irritation due to added preservatives and nonphysiologic chemical composition. A major therapeutic advance took place in 1997, when tobramycin designed for inhalation was approved by the U.S. Food and Drug Administration (FDA) for use in patients with cystic fibrosis (CF) with chronic Pseudomonas aeruginosa infection. Attracted by the clinical benefits observed in CF and the availability of dry powder antibiotic formulations, there has been a growing interest in the use of inhaled antibiotics in other lower respiratory tract infections, such as non-CF bronchiectasis, ventilator-associated pneumonia, chronic obstructive pulmonary disease, mycobacterial disease, and in the post\u2013lung transplant setting over the past decade. Antibiotics currently marketed for inhalation include nebulized and dry powder forms of tobramycin and colistin and nebulized aztreonam. Although both the U.S. Food and Drug Administration and European Medicines Agency have approved their use in CF, they have not been approved in other disease areas due to lack of supportive clinical trial evidence. Injectable formulations of gentamicin, tobramycin, amikacin, ceftazidime, and amphotericin are currently nebulized \u201coff-label\u201d to manage non-CF bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Future inhaled antibiotic trials must focus on disease areas outside of CF with sample sizes large enough to evaluate clinically important endpoints such as exacerbations. Extrapolating from CF, the impact of eradicating organisms such as P. aeruginosa in non-CF bronchiectasis should also be evaluated.<\/jats:p>","DOI":"10.1513\/annalsats.201311-395fr","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T19:30:51Z","timestamp":1395948651000},"page":"425-434","source":"Crossref","is-referenced-by-count":188,"title":["Inhaled Antibiotics for Lower Airway Infections"],"prefix":"10.1093","volume":"11","author":[{"given":"Bradley S.","family":"Quon","sequence":"first","affiliation":[{"name":"James Hogg Research Centre, St. Paul\u2019s Hospital, and Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Goss","sequence":"additional","affiliation":[{"name":"University of Washington, Department of Medicine, Pulmonary and Critical Care Medicine, University of Washington Medical Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie W.","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Center for Clinical and Translational Research, Seattle Children\u2019s Research Institute and Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,3,1]]},"reference":[{"key":"2026012303534691100_bib1","doi-asserted-by":"crossref","first-page":"94S","DOI":"10.1378\/chest.120.3_suppl.94S","article-title":"Formulation of aerosolized therapeutics","volume":"120","author":"Kuhn","year":"2001","journal-title":"Chest"},{"key":"2026012303534691100_bib2","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJM199306173282403","article-title":"Efficacy of aerosolized tobramycin in patients with cystic fibrosis","volume":"328","author":"Ramsey","year":"1993","journal-title":"N Engl J Med"},{"key":"2026012303534691100_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"key":"2026012303534691100_bib4","doi-asserted-by":"crossref","first-page":"mr4","DOI":"10.1126\/scitranslmed.3001634","article-title":"Development of the first inhaled antibiotic for the treatment of cystic fibrosis","volume":"2","author":"Rose","year":"2010","journal-title":"Sci Transl Med"},{"key":"2026012303534691100_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jcf.2009.04.005","article-title":"Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus","volume":"8","author":"Heijerman","year":"2009","journal-title":"J Cyst Fibros"},{"key":"2026012303534691100_bib6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Treatment of lung infection in patients with cystic fibrosis: current and future strategies","volume":"11","author":"D\u00f6ring","year":"2012","journal-title":"J Cyst Fibros"},{"key":"2026012303534691100_bib7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303534691100_bib8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303534691100_bib9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303534691100_bib10","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis","volume":"135","author":"Retsch-Bogart","year":"2009","journal-title":"Chest"},{"key":"2026012303534691100_bib11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ppul.21301","article-title":"An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis","volume":"45","author":"Oermann","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"2026012303534691100_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcf.2004.03.008","article-title":"Early intervention and prevention of lung disease in cystic fibrosis: a European consensus","volume":"3","author":"D\u00f6ring","year":"2004","journal-title":"J Cyst Fibros"},{"issue":"3","key":"2026012303534691100_bib13","first-page":"CD001021","article-title":"Inhaled antibiotics for long-term therapy in cystic fibrosis","author":"Ryan","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012303534691100_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"2026012303534691100_bib15","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa","volume":"183","author":"Geller","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303534691100_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","article-title":"Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection","volume":"185","author":"Trapnell","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303534691100_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303534691100_bib18","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archpediatrics.2011.136","article-title":"Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"165","author":"Treggiari","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2026012303534691100_bib19","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","article-title":"Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis","volume":"167","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303534691100_bib20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"Ratjen","year":"2010","journal-title":"Thorax"},{"key":"2026012303534691100_bib21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ppul.1121","article-title":"Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization","volume":"32","author":"Munck","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"2026012303534691100_bib22","first-page":"CD008319","article-title":"Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis","volume":"12","author":"Ryan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012303534691100_bib23","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thx.2010.136119","article-title":"British Thoracic Society guideline for non-CF bronchiectasis","volume":"65","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"key":"2026012303534691100_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303534691100_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1345\/aph.1E099","article-title":"Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa","volume":"39","author":"Drobnic","year":"2005","journal-title":"Ann Pharmacother"},{"key":"2026012303534691100_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303534691100_bib27","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"2026012303534691100_bib28","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur Respir J"},{"key":"2026012303534691100_bib29","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/jac\/dkm385","article-title":"Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis","volume":"60","author":"Ioannidou","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2026012303534691100_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJM197702172960701","article-title":"Controlled comparison of amikacin and gentamicin","volume":"296","author":"Smith","year":"1977","journal-title":"N Engl J Med"},{"key":"2026012303534691100_bib31","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303534691100_bib32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1164\/rccm.201011-1894OC","article-title":"Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa","volume":"184","author":"Lu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303534691100_bib33","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dkq360","article-title":"Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria","volume":"65","author":"Rattanaumpawan","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2026012303534691100_bib34","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/cc5032","article-title":"Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials","volume":"10","author":"Falagas","year":"2006","journal-title":"Crit Care"},{"key":"2026012303534691100_bib35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1172\/JCI107957","article-title":"Prevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis: II. Effect on the incidence of pneumonia in seriously ill patients","volume":"55","author":"Klick","year":"1975","journal-title":"J Clin Invest"},{"key":"2026012303534691100_bib36","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1378\/chest.113.5.1235","article-title":"Allograft colonization and infections with Pseudomonas in cystic fibrosis lung transplant recipients","volume":"113","author":"Nunley","year":"1998","journal-title":"Chest"},{"key":"2026012303534691100_bib37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-6143.2005.01145.x","article-title":"Donor-to-host transmission of bacterial and fungal infections in lung transplantation","volume":"6","author":"Ruiz","year":"2006","journal-title":"Am J Transplant"},{"key":"2026012303534691100_bib38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1183\/09031936.00201012","article-title":"Inhaled colistin following lung transplantation in colonised cystic fibrosis patients","volume":"42","author":"Suhling","year":"2013","journal-title":"Eur Respir J"},{"key":"2026012303534691100_bib39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/MCP.0b013e3282f9b1d1","article-title":"Fungal infections in lung transplant recipients","volume":"14","author":"Silveira","year":"2008","journal-title":"Curr Opin Pulm Med"},{"key":"2026012303534691100_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1034\/j.1399-3062.2002.t01-2-02002.x","article-title":"The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants","volume":"4","author":"Minari","year":"2002","journal-title":"Transpl Infect Dis"},{"key":"2026012303534691100_bib41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/QCO.0b013e3283630e67","article-title":"Is universal antifungal prophylaxis mandatory in lung transplant patients?","volume":"26","author":"Schaenman","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"2026012303534691100_bib42","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.TP.0000101516.08327.A9","article-title":"Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients","volume":"77","author":"Drew","year":"2004","journal-title":"Transplantation"},{"key":"2026012303534691100_bib43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.healun.2009.11.603","article-title":"Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation","volume":"29","author":"Monforte","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"2026012303534691100_bib44","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0041-1345(96)00363-6","article-title":"Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis","volume":"29","author":"Reichenspurner","year":"1997","journal-title":"Transplant Proc"},{"key":"2026012303534691100_bib45","first-page":"13","article-title":"Anastomotic infections in lung transplant recipients","volume":"5","author":"Hadjiliadis","year":"2000","journal-title":"Ann Transplant"},{"key":"2026012303534691100_bib46","first-page":"1029","article-title":"Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents","volume":"17","author":"Palmer","year":"1998","journal-title":"J Heart Lung Transplant"},{"key":"2026012303534691100_bib47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tube.2010.08.009","article-title":"Inhaled drug therapy for treatment of tuberculosis","volume":"91","author":"Misra","year":"2011","journal-title":"Tuberculosis (Edinb)"},{"key":"2026012303534691100_bib48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-0033-1333575","article-title":"Management of nontuberculous mycobacterial (NTM) lung disease","volume":"34","author":"Philley","year":"2013","journal-title":"Semin Respir Crit Care Med"},{"key":"2026012303534691100_bib49","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1023\/A:1007527204887","article-title":"Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization","volume":"17","author":"O\u2019Hara","year":"2000","journal-title":"Pharm Res"},{"key":"2026012303534691100_bib50","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejps.2007.06.006","article-title":"Inhalable microparticles containing large payload of anti-tuberculosis drugs","volume":"32","author":"Muttil","year":"2007","journal-title":"Eur J Pharm Sci"},{"key":"2026012303534691100_bib51","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2005.12.031","article-title":"Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation","volume":"311","author":"Ricci","year":"2006","journal-title":"Int J Pharm"},{"key":"2026012303534691100_bib52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/jamp.2008.0686","article-title":"Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size","volume":"21","author":"Li","year":"2008","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2026012303534691100_bib53","author":"Olivier","year":"2014"},{"key":"2026012303534691100_bib54","first-page":"A3037","article-title":"A phase 2 study to evaluate the safety, tolerability and efficacy of levofloxacin inhalation solution (mp-376) administered for 5 days every 28 days to prevent acute exacerbations in high risk COPD patients [abstract]","author":"Sethi","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303534691100_bib55","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s12325-008-0105-2","article-title":"Tobramycin nebulizer solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation","volume":"25","author":"Dal Negro","year":"2008","journal-title":"Adv Ther"},{"key":"2026012303534691100_bib56","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/QCO.0b013e328322a006","article-title":"Aerosolized antibiotics to treat ventilator-associated pneumonia","volume":"22","author":"Luyt","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"2026012303534691100_bib57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1183\/09031936.00164508","article-title":"Exhaled nitric oxide in cystic fibrosis: relationships with airway and lung vascular impairments","volume":"34","author":"Hubert","year":"2009","journal-title":"Eur Respir J"},{"key":"2026012303534691100_bib58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using PulmoSphereTM technology","volume":"24","author":"Geller","year":"2011","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2026012303534691100_bib59","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1378\/chest.124.1.360","article-title":"Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers","volume":"124","author":"Newhouse","year":"2003","journal-title":"Chest"},{"key":"2026012303534691100_bib60","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1023\/A:1015322616613","article-title":"Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder","volume":"19","author":"Duddu","year":"2002","journal-title":"Pharm Res"},{"key":"2026012303534691100_bib61","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ppul.21356","article-title":"Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial","volume":"46","author":"Konstan","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"2026012303534691100_bib62","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J Cyst Fibros"},{"key":"2026012303534691100_bib63","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkn059","article-title":"Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections","volume":"61","author":"Meers","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2026012303534691100_bib64","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"key":"2026012303534691100_bib65","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ppul.1125","article-title":"Efficacy and safety of aerosolized tobramycin in cystic fibrosis","volume":"32","author":"Pai","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"2026012303534691100_bib66","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1183\/09031936.02.00264002","article-title":"Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis","volume":"20","author":"Nikolaizik","year":"2002","journal-title":"Eur Respir J"},{"key":"2026012303534691100_bib67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ppul.20736","article-title":"A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"43","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"2026012303534691100_bib68","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1183\/09031936.02.00248102","article-title":"A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis","volume":"20","author":"Hodson","year":"2002","journal-title":"Eur Respir J"},{"key":"2026012303534691100_bib69","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.121.1.55","article-title":"Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis","volume":"121","author":"Moss","year":"2002","journal-title":"Chest"},{"key":"2026012303534691100_bib70","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ppul.10185","article-title":"Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy","volume":"34","author":"Hoffmann","year":"2002","journal-title":"Pediatr Pulmonol"},{"key":"2026012303534691100_bib71","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5414\/CNP66464","article-title":"Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa","volume":"66","author":"Izquierdo","year":"2006","journal-title":"Clin Nephrol"},{"key":"2026012303534691100_bib72","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0025-6196(11)62603-7","article-title":"Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency","volume":"79","author":"Edson","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"2026012303534691100_bib73","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1093\/jac\/dkr303","article-title":"Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI)","volume":"66","author":"Oermann","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2026012303534691100_bib74","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1086\/314727","article-title":"Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis","volume":"179","author":"Burns","year":"1999","journal-title":"J Infect Dis"},{"key":"2026012303534691100_bib75","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ppul.21521","article-title":"Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution","volume":"47","author":"Sawicki","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"2026012303534691100_bib76"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/11\/3\/425\/66484904\/annalsats_11_3_425.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/11\/3\/425\/66484904\/annalsats_11_3_425.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:54:08Z","timestamp":1769158448000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/11\/3\/425\/8431949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,1]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,1]]},"published-print":{"date-parts":[[2014,3,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201311-395fr","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,3]]},"published":{"date-parts":[[2014,3,1]]}}}